Biomics Biopharma (ASX:BBM) Buildings And Improvements : A$0.00 Mil (As of . 20)

View and export this data going back to 2017. Start your Free Trial

What is Biomics Biopharma Buildings And Improvements?

Biomics Biopharma Buildings And Improvements Historical Data

The historical data trend for Biomics Biopharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomics Biopharma Buildings And Improvements Chart

Biomics Biopharma Annual Data

Trend

Buildings And Improvements

Biomics Biopharma Semi-Annual Data

Buildings And Improvements

Biomics Biopharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Biomics Biopharma (ASX:BBM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomics Biopharma Ltd (ASX:BBM) » Definitions » Buildings And Improvements

Comparable Companies

ASX:G88 ASX:ELS ASX:BHD ASX:IBX ASX:ZEN ASX:OLI ASX:KPG ASX:CAN ASX:MPW ASX:CQG ASX:OCA

Traded in Other Exchanges

N/A

Address

1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000

Website

http://www.biomics.com

Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.

Biomics Biopharma (ASX:BBM) Headlines

No Headlines